Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: Efficacy review of AI trials

Cancer and Metastasis Reviews

Volumn 29, Issue 4, 2010, Pages 581-594

  Markopoulos, Christos J ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Anastrozole; Aromatase inhibitors; Distant metastasis; Exemestane; Letrozole; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ARTHRALGIA; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; GENE EXPRESSION PROFILING; HOT FLUSH; HUMAN; MONOTHERAPY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM;

EID: 78449298655     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-010-9248-x     Document Type: Review

References (69)

1. American Cancer Society (2009). Cancer Facts & Figures 2009. Atlanta: American Cancer Society.
2. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy Journal of Clinical Oncology 14 10 2738 2746 1:STN:280:DyaK2s%2FivVehsw%3D%3D 8874335
3. J Houghton 2006 Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T)-data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group Annals of Oncology 17 Suppl. 9 94 Abstract 243PD
4. J Mansell IJ Monypenny AI Skene P Abram R Carpenter JM Gattuso, et al. 2009 Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer Breast Cancer Research and Treatment 117 1 91 98 1:CAS:528:DC%2BD1MXpvFyitbg%3D 10.1007/s10549-008-0291-z 19112615
5. L Lamerato S Havstad S Gandhi D Jones R Chlebowski 2005 Breast cancer recurrence and related mortality in US patients with early breast cancer Journal of Clinical Oncology 23 16S 62s Abstract 738
6. L Mauriac A Keshaviah M Debled H Mouridsen JF Forbes B Thürlimann BIG 1-98 Collaborative Group; International Breast Cancer Study Group, et al. 2007 Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial Annals of Oncology 18 5 859 867 1:STN:280:DC%2BD2s3ns1Kksg%3D%3D 10.1093/annonc/mdm001 17301074
7. JC Doughty 2008 A review of the BIG results: the Breast International Group 1-98 trial analyses Breast 17 Suppl 1 S9 S14 10.1016/S0960-9776(08)70003-1 18279765
8. Doughty, J., Mansell, J., Monypenny, I., Skene A., Abram P., Carpenter R., et al. (2009) Distant recurrence and subsequent mortality in breast cancer patients treated at 5 UK centres. Presented at the St. Gallen Breast Cancer Conference; March 11-14, 2009; St. Gallen, Switzerland. Abstract 188.
9. A Glas A Floore LJ Delahaye AT Witteveen RC Pover N Bakx, et al. 2006 Converting a breast cancer microarray signature into a high-throughput diagnostic test BMC Genomics 7 278 10.1186/1471-2164-7-278 17074082
10. MG Lê R Arriagada M Spielmann J-M Guinebretiére F Rochard 2002 Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma Cancer 94 11 2813 2820 10.1002/cncr.10572 12115367
11. B Thurlimann A Keshaviah AS Coates H Mouridsen L Mauriac JF Forbes For the Breast International Group (BIG) 1-98 Collaborative Group, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer The New England Journal of Medicine 353 26 2747 2757 10.1056/NEJMoa052258 16382061
12. A Howell J Cuzick M Baum A Buzdar M Dowsett JF Forbes, et al. 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 9453 60 62 1:STN:280:DC%2BD2M%2FhsVartA%3D%3D 10.1016/S0140-6736(04)17666-6 15639680
13. AS Coates A Keshaviah B Thurlimann H Mouridsen L Mauriac JF Forbes, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 Journal of Clinical Oncology 25 5 486 492 1:CAS:528:DC%2BD2sXivF2mt7Y%3D 10.1200/JCO.2006.08.8617 17200148
14. RC Coombes LS Kilburn CF Snowdon R Paridaens RE Coleman SE Jones Intergroup Exemestane Study, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 9561 559 570 1:CAS:528:DC%2BD2sXhvVGgsro%3D 10.1016/S0140-6736(07)60200-1 17307102
15. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group JF Forbes J Cuzick A Buzdar, et al. 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncology 9 1 45 53 10.1016/S1470-2045(07)70385-6 18083636
16. H Mouridsen A Giobbie-Hurder A Goldhirsch B Thürlimann R Paridaens I Smith BIG 1-98 Collaborative Group, et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer The New England Journal of Medicine 361 (8) 766 776 1:CAS:528:DC%2BD1MXhtVWls7fM 19692688
17. A Goldhirsch JN Ingle RD Gelber AS Coates B Thürlimann HJ Senn Panel members 2009 Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Annals of Oncology 20 8 1319 1329 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D 10.1093/annonc/mdp322 19535820
18. M Debled G MacGrogan V Brouste S Mathoulin-Pelissier M Durand L Mauriac 2007 Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis Cancer 109 11 2197 2204 1:CAS:528:DC%2BD2sXmvVKjsLg%3D 10.1002/cncr.22667 17450590
19. A Goldhirsch WC Wood RD Gelber AS Coates B Thurlimann HJ Senn, et al. 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Annals of Oncology 18 7 1133 1144 1:STN:280:DC%2BD2svlvVSkuw%3D%3D 10.1093/annonc/mdm271 17675394 Erratum in: Annals of Oncology 2007; 18(11), 1917
20. SY Jung W Han JW Lee E Ko E Kim JH Yu, et al. 2009 Ki-67 expression gives additional prognostic information on St. Gallen, 2007 and Adjuvant! Online risk categories in early breast cancer Annals of Surgical Oncology 16 5 1112 1121 10.1245/s10434-009-0334-7 19219507
21. C Sotiriou L Pusztai 2009 Gene-expression signatures in breast cancer The New England Journal of Medicine 360 8 790 800 1:CAS:528:DC%2BD1MXitFWqs70%3D 10.1056/NEJMra0801289 19228622
22. S Paik S Shak G Tang C Kim J Baker M Cronin, et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer The New England Journal of Medicine 351 27 2817 1:CAS:528:DC%2BD2MXhslymsw%3D%3D 10.1056/NEJMoa041588 15591335
23. S Paik C Kim J Baker W Kim M Cronin FL Baehner, et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer Journal of Clinical Oncology 24 23 3726 3734 1:CAS:528:DC%2BD28XpsVaqsrs%3D 10.1200/JCO.2005.04.7985 16720680
24. JA Sparano 2006 TAILORx: trial assigning individualized options for treatment (Rx) Clinical Breast Cancer 7 4 347 350 10.3816/CBC.2006.n.051 17092406
25. M Dowsett J Cuzick C Wales J Forbes I Mallon J Salter On behalf of the ATAC Trialists' Group, et al. 2009 Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study Cancer Research 69 Suppl 75s Abstract 53
26. F Cardoso M Piccart-Gebhart L Van't Veer E Rutgers TRANSBIG Consortium 2007 The MINDACT trial: the first prospective clinical validation of a genomic tool Molecular Oncology 1 3 246 251 10.1016/j.molonc.2007.10.004 19383299
27. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0
28. L Del Mastro M Clavarezza M Venturini 2007 Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors Cancer Treat Reviews 33 8 681 687 10.1016/j.ctrv.2007.07.014
29. B Fisher J Dignam J Bryant N Wolmark 2001 Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial Journal of the National Cancer Institute 93 9 684 690 1:CAS:528: DC%2BD3MXjvVamu70%3D 10.1093/jnci/93.9.684 11333290
30. LE Rutqvist H Johansson Stockholm Breast Cancer Study Group 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer Acta Oncology 46 2 133 145 1:CAS:528:DC%2BD2sXjs1GlsL0%3D 10.1080/02841860601034834
31. MP Goetz SK Knox VJ Suman JM Rae SL Safgren MM Ames, et al. 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Research and Treatment 101 1 113 121 1:CAS:528: DC%2BD2sXisVylsg%3D%3D 10.1007/s10549-006-9428-0 17115111
32. W Schroth MP Goetz U Hamann PA Fasching M Schmidt S Winter, et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen Journal of the American Medical Association 302 13 1429 1436 1:CAS:528:DC%2BD1MXht1CksrjO 10.1001/jama.2009.1420 19809024
33. Aubert, R. E., Stanek, E. J., Yao, J., Teagarden, J. R., Subar, M., Epstein, R. S., et al. (2009) Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of Clinical Oncology 27(18 S). Abstract CRA508.
34. EA Perez 2007 Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer Annals of Oncology 18 Suppl 8 26 35
35. PE Lønning J Geisler 2008 Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression The Journal of Steroid Biochemistry and Molecular Biology 108 3-5 196 202 10.1016/j.jsbmb.2007.09.017 17996443
36. A Buzdar R Chlebowski J Cuzick S Duffy J Forbes W Jonat, et al. 2006 Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer Current Medical Research and Opinion 22 8 1575 1585 1:CAS:528:DC%2BD28XhtVWhu73K 10.1185/030079906X120940 16870082
37. J Geisler H Helle D Ekse NK Duong DB Evans Y Nordbø, et al. 2008 Letrozole is superior to anastrozole suppressing breast cancer tissue and plasma estrogen levels Clinical Cancer Research 14 19 6330 6335 1:CAS:528: DC%2BD1cXhtF2nurbM 10.1158/1078-0432.CCR-07-5221 18829517
38. M Baum AU Budzar J Cuzick J Forbes JH Houghton JG Klijn ATAC Trialists' Group.ATAC Trialists' Group, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 9324 2131 2139 1:CAS:528:DC%2BD38XkslGhsLY%3D 10.1016/S0140-6736(02) 09088-8 12090977
39. SE Jones C Seynaeve A Hasenburg D Rae J-M Vannetzel R Paridaens, et al. 2009 Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer Cancer Research 69 Suppl 66s
40. D Rea A Hasenburg C Seynaeve SE Jones JM Vannetzel R Paridaens, et al. 2009 Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for five years: the TEAM trial, a prospective, randomized, phase iii trial in postmenopausal women with hormone-sensitive early breast cancer Cancer Research 69 Suppl s24
41. RC Coombes E Hall LJ Gibson R Paridaens J Jassem T Delozier Intergroup Exemestane Study, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer The New England Journal of Medicine 350 11 1081 1092 1:CAS:528: DC%2BD2cXitV2qtbc%3D 10.1056/NEJMoa040331 15014181
42. R Jakesz W Jonat M Gnant M Mittlboeck R Greil C Tausch ABCSG and the GABG, et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 9484 455 462 1:CAS:528:DC%2BD2MXntVeisLw%3D 10.1016/S0140-6736(05)67059-6 16084253
43. F Boccardo A Rubagotti M Puntoni P Guglielmini D Amoroso A Fini, et al. 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial Journal of Clinical Oncology 23 22 5138 5147 1:CAS:528:DC%2BD2MXpsFWmtb4%3D 10.1200/JCO.2005.04.120 16009955
44. PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart, et al. 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 Journal of the National Cancer Institute 97 17 1262 1271 1:CAS:528:DC%2BD2MXpvFKjsrY%3D 10.1093/jnci/dji250 16145047
45. R Jakesz R Greil M Gnant M Schmid W Kwasny E Kubista Austrian Breast and Colorectal Cancer Study Group, et al. 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a Journal of the National Cancer Institute 99 24 1845 1853 1:CAS:528:DC%2BD1cXhtVOrtL0%3D 10.1093/jnci/djm246 18073378 Erratum in: Journal of the National Cancer Institute 2008; 100(3), 226
46. EP Mamounas 2001 Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial Oncology 15 5 Suppl 7 35 39 1:STN:280:DC%2BD3MzivVOmtA%3D%3D 11396363
47. EP Mamounas JH Jeong DL Wickerham RE Smith PA Ganz SR Land, et al. 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial Journal of Clinical Oncology 26 12 1965 19671 1:CAS:528:DC%2BD1cXlvFaqs74%3D 10.1200/JCO.2007.14.0228 18332472
48. Howell, A., Forbes, J., & Cuzick, J. (2009) Initial adjuvant therapy with anastrozole-early and late event data from the arimidex, tamoxifen, alone or in combination (ATAC) trial in the hormone-responsive population. Presented at the St. Gallen Breast Cancer Conference; March 11-14; St. Gallen, Switzerland. Abstract 0130.
49. Thurlimann B; BIG 1-98 Collaborative Group (2009) Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Update of the BIG 1-98 primary core analysis. Presented at the St. Gallen Breast Cancer Conference; March 11-14; St. Gallen, Switzerland. Abstract 0161.
50. JM Robins DM Finkelstein 2000 Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests Biometrics 56 3 779 788 1:STN:280: DC%2BD3M%2Fms1yisg%3D%3D 10.1111/j.0006-341X.2000.00779.x 10985216
51. Regan, M. M., Colleoni, M., Giobbie-Hurder, A., Thuerlimann, B., Mouridsen, H., Mauriac, L., et al. (2009) Adjusting for selective crossover in analyses of letrozole (Let) versus tamoxifen (Tam) in the BIG 1-98 trial. Cancer Research 69(24 Suppl). Abstract 16.
52. R DeBoer H Burris A Monnier H Mouridsen J O'Shaughnessy K McIntyre 2006 The head to head trial: letrozole vs. anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer Journal of Clinical Oncology 24 18S 582s Abstract 10672
53. A Monnier 2006 Refining the postmenopausal breast cancer treatment paradigm: the FACE trial Expert Review of Anticancer Therapy 6 10 1355 1359 10.1586/14737140.6.10.1355 17069521
54. C van de Velde CH Seynaeve A Hasenburg D Rea JM Vannetzel R Paridaens, et al. 2009 Results of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer European Journal of Cancer Supplements 7 3 1 10.1016/S1359- 6349(09)72025-7 Abstract 2BA
55. M Kaufmann W Jonat J Hilfrich H Eidtmann G Gademann I Zuna, et al. 2007 Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study Journal of Clinical Oncology 25 19 2664 2670 1:CAS:528:DC%2BD2sXosValt7Y%3D 10.1200/JCO.2006.08.8054 17563395
56. Bliss, J. M., Kilburn, L. S., Coleman, R. E., Forbes, J. F., Coates, A. S., Jones, S. E., et al. (2009) Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES). Cancer Research 69(24 Suppl). Abstract 12.
57. W Jonat M Gnant F Boccardo M Kaufmann A Rubagotti I Zuna, et al. 2006 Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis The Lancet Oncology 7 12 991 996 1:CAS:528:DC%2BD28Xht1KrsbzM 10.1016/S1470-2045(06)70948-2 17138220
58. R Jakesz N Gnant R Greil C Tausch H Samonigg W Kwasny, et al. 2005 The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year analysis of ABCSG Trial 8 Breast Cancer Research and Treatment 94 Suppl 1 S10 Abstract 13
59. R Jakesz M Gnant R Griel C Tausch H Samonigg W Kwasny, et al. 2009 Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8 Cancer Research 69 Suppl 67s Abstract 14
60. HT Mouridsen A Giobbie-Hurder L Mauriac R Paridaens M Colleoni B Thuerlimann, et al. 2009 BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer Cancer Research 69 Suppl 2 66s Abstract 13
61. PE Goss JN Ingle S Martino NJ Robert HB Muss MJ Piccart, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer The New England Journal of Medicine 349 19 1793 1802 1:CAS:528:DC%2BD3sXosl2gtbc%3D 10.1056/NEJMoa032312 14551341
62. PE Goss JN Ingle JL Pater S Martino NJ Robert HB Muss, et al. 2008 Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen Journal of Clinical Oncology 26 12 1948 1955 1:CAS:528:DC%2BD1cXlvFaqsrY%3D 10.1200/JCO.2007.11.6798 18332475
63. Goss, P. E., Ingle, J. N., Martino, S., Robert, N., Muss, H., Shepherd, L., et al. (2009) Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial. Cancer Research 69(24 Suppl):Abstract 13.
64. HF Kennecke IA Olivotto C Speers B Norris SK Chia C Bryce, et al. 2007 Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen Annals of Oncology 18 1 45 51 1:STN:280:DC%2BD2s%2FisVWnug%3D%3D 10.1093/annonc/mdl334 17030545
65. JN Ingle M Dowsett J Cuzick C Davies For the Aromatase Inhibitors Overview Group (AIOG) 2009 Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies Cancer Research 69 Suppl 2 66s Abstract 12
66. M Dowsett J Cuzick J Ingle A Coates J Forbes J Bliss, et al. 2010 Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen Journal of Clinical Oncology 28 3 509 518 1:CAS:528:DC%2BC3cXivFartbk%3D 10.1200/JCO.2009.23.1274 19949017
67. Goss, P. E., Mamounas, E. P., Jakesz, R., Markopoulos, C., Dowsett, M., Peto, R., et al. (2009) Aromatase inhibitors (AIs) versus not (placebo/observation) as late extended adjuvant therapy for postmenopausal women with early stage breast cancer (BC): overviews of randomized trials of AIs after 5 years of tamoxifen. Cancer Research 69(24 Suppl), Abstract 4081.
68. C Markopoulos U Dafni J Misitzis V Zobolas E Tzoracoleftherakis D Koukouras, et al. 2009 Extended adjuvant hormonal therapy with exemestane has no detrimental effect on the lipid profile of postmenopausal breast cancer patients: final results of the ATENA lipid substudy Breast Cancer Research 11 3 R35 10.1186/bcr2320 19531217
69. JM Dixon L Renshaw O Young J Murray EJ Macaskill M McHugh, et al. 2008 Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer Journal of Clinical Oncology 26 10 1671 1676 1:CAS:528:DC%2BD1cXltlWhsrk%3D 10.1200/JCO.2007.13.9279 18375896